Phase II IL-7 (CYT107)

[John2038]

Cytheris Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7 (CYT107) in Chronically Infected HIV Patients Who Fail to Achieve Optimal Immune Reconstitution under HAART Therapy

PARIS, FRANCE | January 12, 2010 | Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART). The phase IIa study is designed to evaluate the biological activity and pharmacokinetic (PK) profile of CYT107 at a dose of 20 µg/kg/week in patients with CD4 counts of 101-400 cells/µL. The study will be conducted across 4 investigative sites in the United States and Canada.

Full Text

[Inchlingblue]

Cytheris Announces Notice of Allowance for U.S. Patent Covering the Preparation and Uses of Its Glycosylated Recombinant Human Interleukin-7 (CYT107)


PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

Continued . . .

LINK:

http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100202005885&newsLang=en